A Phase II Study of Cladribine and Low Dose Cytarabine in Combination With Venetoclax, Alternating With Azacitidine and Venetoclax, in Patients With Higher-risk Myeloproliferative Chronic Myelomonocytic Leukemia or Higher-risk Myelodysplastic Syndromes With Excess Blasts

Last updated: May 14, 2025
Sponsor: M.D. Anderson Cancer Center
Overall Status: Active - Recruiting

Phase

2

Condition

Leukemia

Myelodysplastic Syndromes (Mds)

White Cell Disorders

Treatment

Cytarabine

Azacitidine

Venetoclax

Clinical Study ID

NCT05365035
2021-1116
NCI-2022-03803
  • Ages > 18
  • All Genders

Study Summary

To learn if the combination of cladribine, cytarabine, venetoclax, and azacitidine can help to control higher-risk myelodysplastic syndrome (MDS) with excess blasts and/or higher-risk chronic myelomonocytic leukemia (CMML).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Age >/= 18 years.

  2. Diagnosis of MDS or CMML by WHO and:

  • MDS relapsed cohort (Cohort A): MDS with Int-2 or High risk IPSS and >5% blastswith no response after 6 cycles of azacitidine, decitabine, guadecitabine,CC-486 or ASTX727 (decitabine/cedazuridine) or relapse or progression after anynumber of cycles

  • CMML relapsed cohort (Cohort B): CMML 1 or 2 with no response after 6 cycles ofazacitidine, decitabine, guadecitabine, CC-486 or ASTX727 (decitabine/cedazuridine) or relapse or progression after any number of cycles

  • MDS HMA-naïve cohort (Cohort C): MDS with Int-2 or High risk by IPSS and >10%blasts OR diagnosis

  • CMML HMA-naïve cohort (Cohort D): CMML-2; OR CMML-1 with at least one of thefollowing high-risk features: extramedullary disease, splenomegaly of >5cmbelow costal margin, platelets <100x109/L, Hgb level <10g/dL, WBC >13x109/L,clonal cytogenetic abnormality (other than monosomy Y).

  1. Eastern Cooperative Oncology Group (ECOG) performance status of </= 2

  2. Creatinine clearance > 30 ml/min no end/stage renal disease (using Cockcroft-Gault)

  3. Adequate hepatic function with total bilirubin 2x ULN, AST or ALT 2.5 xULN unlessdeemed to be due to underlying disease involvement.

  4. Willing to adhere to and comply with all prohibitions and restrictions specified inthe protocol.

  5. Patient must have signed an informed consent document indicating that the patientunderstands the purpose of and procedures required for the study and is willing toparticipate in the study.

  6. White blood cell (WBC) count <50,000/L. Hydroxyurea may be used to controlleukocytosis prior to C1D1. Use of hydroxyurea beyond this point may be permitted asclinically indicated, on a case-by-case basis and after discussion with the PI.

  7. English and Non-English speaking patients will be allowed

Exclusion

Exclusion Criteria:

  1. Uncontrolled infection not adequately responding to appropriate antibiotics

  2. New York Heart Association (NYHA) Class III or IV congestive heart failure or LVEF <50% by echocardiogram or multigated acquisition (MUGA) scan.

  3. History of myocardial infarction within the last 6 months or unstable/uncontrolledangina pectoris or history of severe and/or uncontrolled ventricular arrhythmias.

  4. Female patients who are pregnant or lactating.

  5. Patients with reproductive potential who are unwilling to following contraceptionrequirements (including condom use for males with sexual partners, and for females:prescription oral contraceptives [birth control pills], contraceptive injections,intrauterine devices [IUD], double-barrier method [spermidical jelly or foam withcondoms or diaphragm], contraceptive patch, or surgical sterilization) throughoutthe study.

  6. Female patients with reproductive potential who do not have a negative urine orblood beta-human chorionic gonadotropin (beta HCG) pregnancy test at screening.

  7. Patients receiving any other concurrent investigational agent or chemotherapy,radiotherapy, or immunotherapy.

Study Design

Total Participants: 60
Treatment Group(s): 4
Primary Treatment: Cytarabine
Phase: 2
Study Start date:
September 23, 2022
Estimated Completion Date:
December 01, 2025

Study Description

Primary Objectives:

  • To determine the efficacy, safety and tolerability of the combination of cladribine, cytarabine and venetoclax in higher-risk MDS with excess blasts and higher-risk CMML.

  • MDS relapsed cohort (Cohort A, N=20): MDS with Int-2 or High risk IPSS and >5% blasts with no response after 6 cycles of azacitidine, decitabine, guadecitabine, CC-486 or ASTX727 (decitabine/cedazuridine) or relapse or progression after any number of cycles

  • CMML relapsed cohort (Cohort B, N=10): CMML 1 or 2 with no response after 6 cycles of azacitidine, decitabine, guadecitabine, CC-486 or ASTX727 (decitabine/cedazuridine) or relapse or progression after any number of cycles

  • MDS HMA-naïve cohort (Cohort C, N=20): MDS with Int-2 or High risk by IPSS and >10% blasts OR diagnosis

  • CMML HMA-naïve cohort (Cohort D, N=10): CMML-2; OR CMML-1 with at least one of the following high-risk features: extramedullary disease, splenomegaly of >5cm below costal margin, platelets <100x109/L, Hgb level <10g/dL, WBC >13x109/L, clonal cytogenetic abnormality (other than monosomy Y).

Secondary Objectives:

  • To assess overall survival (OS), duration of response, leukemia-free survival (LFS), and relapse-free survival (RFS).

  • To evaluate proportion of transplant-candidate patients bridged to allogeneic stem-cell transplant.

  • Correlative studies including correlation of response with disease subtype and genomic profile.

  • To evaluate changes in clonal composition and VAF of identified mutations with therapy.

Connect with a study center

  • M D Anderson Cancer Center

    Houston, Texas 77030
    United States

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.